07-722
Anti-phospho-VEGFR2/Flk-1/KDR (Tyr1054) Antibody
Upstate®, from rabbit
别名:
Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, kinase insert domain receptor (a type III receptor tyrosine kinase), vascular endothelial growth factor receptor 2
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
polyclonal
Species reactivity:
zebrafish, human
Application:
western blot
Technique(s):
western blot: suitable
Citations:
3
Uniprot accession no.:
产品名称
Anti-phospho-VEGFR2/Flk-1/KDR (Tyr1054) Antibody, Upstate®, from rabbit
biological source
rabbit
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
zebrafish, human
species reactivity (predicted by homology)
primate (based on 100% sequence homology), horse (based on 100% sequence homology), rat (based on 100% sequence homology), mouse (based on 100% sequence homology), chicken (based on 100% sequence homology), bovine (based on 100% sequence homology), Danio (based on 100% sequence homology)
manufacturer/tradename
Upstate®
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
phosphorylation (pTyr1054)
Quality Level
Gene Information
human ... KDR(3791)
Analysis Note
Control
CSF-1 treated PAE cell lysate, transfected with CSF/KDR.
CSF-1 treated PAE cell lysate, transfected with CSF/KDR.
Western Blot Analysis:
This lot detected VEGFR2 phosphorylated on Tyr1054 at a 1:1,000 dilution in PAE cells transfected with CSF/KDR and treated with 40ng/mL CSF-1 for 15 min. Cell lysate resolved via SDS-PAGE and transferred to PVDF (Immobilon-P).
This lot detected VEGFR2 phosphorylated on Tyr1054 at a 1:1,000 dilution in PAE cells transfected with CSF/KDR and treated with 40ng/mL CSF-1 for 15 min. Cell lysate resolved via SDS-PAGE and transferred to PVDF (Immobilon-P).
Application
Anti-phospho-VEGFR2/Flk-1/KDR (Tyr1054) Antibody is an antibody against phospho-VEGFR2/Flk-1/KDR (Tyr1054) for use in WB.
Research Category
Signaling
Signaling
Biochem/physiol Actions
Recognizes VEGFR2/Flk-1/KDR when phosphorylated on Tyrosine 1054 (human).
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
152 kDa
The Flt gene family of receptor tyrosine kinases includes Flt-1, KDR/Flk-1, Flt-3, and Flt-4. They encode receptors for VEGF, characterized by seven Ig-loops within their extracellular domain and a split kinase domain within the cytoplasmic domain. VEGF is an important angiogenic factor of many solid tumors and is also involved in the differentiation of endothelial cells. Flt-1 (Fms-like tyrosine kinase, VEGF-R1) is expressed on endothelial cells and on the common precursors of endothelial and hematopoietic stem cells. KDR (Flk-1, VEGF-R2) is the principal receptor involved in VEGF signaling. KDR is expressed on endothelial cells and stimulates angiogenesis, but is also expressed on bone marrow cells, and is thought to play a role in driving the proliferation of most or all leukemic cells. Flt3 (also known as Flk-2) is a class III receptor tyrosine kinase that is closely related to c-Kit and c-Fms. It is expressed in primitive hematopoietic cells and its ligand exerts proliferative effects on these cells in co-operation with other cytokines.
Immunogen
Synthetic peptide encompassing
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Affinity purified rabbit polyclonal IgG in PBS with 0.05% NaN3 and 50% glycerol.
Double affinity purified
Preparation Note
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
Valentin Derangère et al.
Oncotarget, 7(8), 9309-9321 (2016-01-30)
Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one
Edward Hartsough et al.
iScience, 25(8), 104736-104736 (2022-08-10)
Through tightly controlled multilayer mechanisms, vascular endothelial growth factor receptor-2 (VEGFR-2) activation and its downstream signal transduction govern vasculogenesis and pathological angiogenesis, such as tumor angiogenesis. Therefore, it is critical to understand the molecular mechanisms governing VEGFR-2 signal transduction. We
Anthony Ambesi et al.
Journal of cell science, 127(Pt 17), 3805-3816 (2014-07-02)
The fibronectin matrix plays a crucial role in the regulation of angiogenesis during development, tissue repair and pathogenesis. Previous work has identified a fibronectin-derived homophilic binding peptide, anastellin, as an effective inhibitor of angiogenesis; however, its mechanism of action is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持